Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.
Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...
Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...
Live Science on MSN17h
Severe COVID-19 may shrink cancer tumors, early data suggestImmune cells produced during severe COVID-19 infection may shrink tumors. The unexpected mechanism offers a new therapeutic ...
Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...
Phase 3 trial results support toripalimab plus chemotherapy as a first-line treatment option for patients with ES-SCLC, researchers say.
Researchers have tested a novel therapeutic concept to treat virus-induced lung failure in patients with severe COVID-19 in a phase 2 clinical trial. The approach may also be applicable to other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback